News
OCUL
5.09
+0.30%
0.02
Weekly Report: what happened at OCUL last week (0415-0419)?
Weekly Report · 1d ago
Optimistic Buy Rating for Ocular Therapeutix Amid Early-Stage NPDR Study and Wet AMD Potential
TipRanks · 1d ago
Baird sees weakness in Ocular shares "overdone" in wake of Phase 1 data
Baird sees weakness in Ocular shares as "overdone" and remains bullish on the company's opportunity in wet AMD. The investment firm said results from the Phase 1 Helios study of Axpaxli showed no notable safety issues. Baird maintained its outperform rating on the stock with a price target of $18.
Seeking Alpha · 3d ago
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Super Micro Computer, Inc. Shares fell 13.2% to $806.00 on Friday. The company announced its third-quarter earnings date and did not provide preliminary estimates. Next.e.GO shares jumped 129% in the mid-day session. Redwoods Acquisition Corp. Shares rose 62.5% after falling around 3%.
Benzinga · 4d ago
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)
TipRanks · 4d ago
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $16 Price Target
Benzinga · 4d ago
Ocular Therapeutix Announces New Leadership and Incentive Plan Expansion
TipRanks · 4d ago
Correction to Ocular Therapeutix Shares Dive Article
Ocular shares are up 43% year-to-date and were trading at around $5.73 this time a year ago. The company's shares were in negative territory last week. The shares are now up to $15.61. A previous version of this article incorrectly said shares of ocular Therapeutix were down.
Dow Jones · 5d ago
Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
Ocular Therapeutix announces topline results from the Phase 1 HELIOS study of Axpaxli in patients with diabetic retinopathy without diabetic macular edema. The company says results support the decision to move directly to a Phase 3 study with the drug.
Benzinga · 5d ago
Ocular Therapeutix Shares Dive on Axpaxli Trial Results
Shares of Ocular Therapeutix fell 15% in midday trading. The company reported topline data for a Phase 1 trial of its diabetic retinopathy drug candidate Axpaxli. Shares are now in negative territory year-to-date. Ocular says it will accelerate to Phase 3 of its drug candidate.
Dow Jones · 5d ago
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Las Vegas Sands Corp. Shares dipped 6.8% to $46.81 on Thursday. The company reported better-than-expected first-quarter results. AGBA Group Holding Limited shares jumped 148% after the company announced a merger agreement with Triller. Other stocks moving in the mid-day session included 23andMe Holding Co. And Vertex Pharmaceuticals.
Benzinga · 5d ago
Ocular marks early-stage trial win for diabetic retinopathy candidate
Seeking Alpha · 5d ago
Ocular Therapeutix Reports Topline Phase 1 Data For AXPAXLI In Diabetic Retinopathy; AXPAXLI Was Generally Well Tolerated With No Inflammation Observed
6 of 13 patients in the AXPAXLI group experienced a 1 or 2-step improvement in the Diabetic Retinopathy Severity Scale. The drug was generally well tolerated with no inflammation observed. Ocular plans to present the study results at an upcoming meeting.
Benzinga · 5d ago
OCULAR THERAPEUTIX - 46.2% OF PATIENTS SHOWED A 1- OR 2-STEP IMPROVEMENT IN DIABETIC RETINOPATHY SEVERITY SCALE (DRSS) AT 40 WEEKS IN AXPAXLI ARM
Reuters · 5d ago
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Ocular Therapeutix (OCUL) and Elevance Health (ELV)
TipRanks · 6d ago
ENPH, OCUL and ITCI are among after hour movers
Seeking Alpha · 6d ago
The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts
Ocular Therapeutix is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The average price target for the company is $17.5, with a 12-month target of $24.00. 8 analysts have recently shared their insights on the company. The company has a positive revenue growth rate of 5.16% over the past year.
Benzinga · 04/16 17:01
Ocular Therapeutix Price Target Maintained With a $24.00/Share by JMP Securities
Dow Jones · 04/16 15:22
JMP Securities Reiterates Market Outperform on Ocular Therapeutix, Maintains $24 Price Target
Benzinga · 04/16 15:13
*Ocular Therapeutix: Nadia K. Waheed Appointed Chief Medical Officer >OCUL
Dow Jones · 04/16 11:01
More
Webull provides a variety of real-time OCUL stock news. You can receive the latest news about Ocular Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. It is also developing two other clinical-stage assets, OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease. It is conducting a pivotal Phase III clinical trial to evaluate AXPAXLI for the treatment of wet AMD. Its clinical portfolio also includes PAXTRAVA, which is in Phase III clinical development for the treatment of primary open-angle glaucoma (OAG) or ocular hypertension (OHT).